or Try an Advanced Search...

    Technical Analysis for IKNA - Ikena Oncology, Inc.

    Grade Last Price % Change Price Change
    D 1.65 0.00% 0.00
    IKNA closed unchanged on Monday, July 1, 2024, on 82 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical IKNA trend table...
    Date Alert Name Type % Chg
    BB Squeeze Ended Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Fell Below 20 DMA Bearish 0.00%
    Volume Surge Other 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Crossed Above 20 DMA Bullish -5.71%
    Bollinger Band Squeeze Range Contraction -5.71%
    BB Squeeze + Lower Band Touch Range Contraction -5.71%
    Lower Bollinger Band Touch Weakness -5.71%
    Older End-of-Day Signals for IKNA ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 6 hours ago
    60 Minute Opening Range Breakout about 8 hours ago
    Up 1% about 10 hours ago
    Down 3% about 10 hours ago
    Fell Below Lower Bollinger Band about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    IKNA Chart by TradingView
    Basic chart:

    Profile

    Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer

    Is IKNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 1 It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
    May 29 Wedbush downgrades Ikena, cites discontinuation of lead asset
    May 28 Ikena to cut workforce by 53%, explore strategic options
    May 28 UPDATE – Ikena Oncology Announces Strategic Update
    May 28 Ikena Oncology Announces Strategic Update
    May 14 Ikena Oncology reports Q1 GAAP EPS of -$0.33
    May 13 Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
    Apr 10 Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
    Mar 14 Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
    Mar 12 Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
    See more IKNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.94
    52 Week Low 1.02
    Average Volume 383,846
    200-Day Moving Average 2.05
    50-Day Moving Average 1.52
    20-Day Moving Average 1.73
    10-Day Moving Average 1.69
    Average True Range 0.09
    RSI (14) 50.50
    ADX 36.05
    +DI 23.39
    -DI 16.58
    Chandelier Exit (Long, 3 ATRs) 1.61
    Chandelier Exit (Short, 3 ATRs) 1.88
    Upper Bollinger Bands 1.83
    Lower Bollinger Band 1.62
    Percent B (%b) 0.12
    BandWidth 12.10
    MACD Line 0.04
    MACD Signal Line 0.06
    MACD Histogram -0.0227
    Fundamentals Value
    Market Cap 79.63 Million
    Num Shares 48.3 Million
    EPS -1.62
    Price-to-Earnings (P/E) Ratio -1.02
    Price-to-Sales 4.84
    Price-to-Book 0.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.79
    Resistance 3 (R3) 1.78 1.74 1.76
    Resistance 2 (R2) 1.74 1.70 1.74 1.75
    Resistance 1 (R1) 1.69 1.68 1.72 1.70 1.75
    Pivot Point 1.65 1.65 1.66 1.65 1.65
    Support 1 (S1) 1.60 1.61 1.63 1.61 1.55
    Support 2 (S2) 1.56 1.59 1.56 1.55
    Support 3 (S3) 1.51 1.56 1.54
    Support 4 (S4) 1.52